Camrelizumab Clinical Trials
48 recruitingDrug
Phase 232Phase 17Phase 37Not Applicable3Early Phase 11
Showing 1–20 of 48 trials
Recruiting
Phase 2
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Gastric CancerSecond-line Therapy
Shandong Tumor Hospital40 enrolled1 locationNCT07320586
Recruiting
Phase 2
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
HCC
GrandPharma (China) Co., Ltd.120 enrolled3 locationsNCT07334483
Recruiting
Phase 2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital300 enrolled1 locationNCT07157969
Recruiting
Phase 2
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Endometrioid Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University39 enrolled1 locationNCT06561308
Recruiting
Not Applicable
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University43 enrolled1 locationNCT05772273
Recruiting
Not Applicable
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Colon CancerImmunotherapyMismatch Repair Deficiency
Peking Union Medical College Hospital18 enrolled2 locationsNCT06215677
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Hepatocellular Carcinoma (HCC)
Fudan University141 enrolled1 locationNCT07100392
Recruiting
Phase 2
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
Mixed Hepatocellular-cholangiocarcinoma
Fudan University45 enrolled1 locationNCT07105748
Recruiting
Phase 2
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital90 enrolled1 locationNCT07057089
Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaBevacizumabAnti-PD1/PDL1 Antibody
Sun Yat-sen University240 enrolled1 locationNCT06323382
Recruiting
Phase 2
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Adrenal Cortical CancerAdrenal Cortical CarcinomaAdrenal Cancer
West China Hospital28 enrolled1 locationNCT06831175
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Phase 2
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
MelanomaAcral MelanomaNeoadjuvant+4 more
Peking University Cancer Hospital & Institute60 enrolled1 locationNCT05512481
Recruiting
Phase 2
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Fudan University25 enrolled1 locationNCT04299581
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Hepatocellular CarcinomaPD-1 InhibitorLenvatinib+1 more
Sun Yat-sen University300 enrolled1 locationNCT06333561
Recruiting
Phase 3
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular CarcinomaImmunotherapyPreoperative
The First Affiliated Hospital with Nanjing Medical University130 enrolled1 locationNCT05613478
Recruiting
Phase 1
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Esophageal Squamous Cell Carcinoma
West China Hospital6 enrolled1 locationNCT06654297
Recruiting
Phase 2
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
HER2-negative Breast CancerBRCA-Mutated Breast Carcinoma
Fudan University130 enrolled1 locationNCT06516289
Recruiting
Phase 2
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Cervical CancerFertility PreservationNeoadjuvant Chemoimmunotherapy
Tongji Hospital40 enrolled2 locationsNCT06289062